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Sirs,
Spurred by the reported spectacular results of eculizumab
treatment in atypical hemolytic uremic syndrome (aHUS)
due to aberrations in the complement system, an increasing
number of children will receive this treatment in future. The
main adverse effect of this therapy is an increased
susceptibility to meningococcal infection due to inhibition
of the complement system’s membrane-attack complex. In
patients with paroxysmal nocturnal hemoglobinuria treated
with eculizumab, the reported occurrence of meningococcal
infection is between 0% and 1.5% [1–3]. These data,
concerning adult patients, cannot be extrapolated to children
because the age-specific incidence of meningococcal disease
is much higher in children.
According to the medication guide of the U.S. Food and
Drug Administration, a tetravalent unconjugated polysaccha-
ride vaccine (serogroups A, C, Y , W135) has to be provided at
least 2 weeks before the first dose of eculizumab. In our
opinion, this approach is not sufficient for prevention in many
countries, because none of the available vaccines contains a
serogroup B antigen [4]. The serogroup distribution among
meningococcal infections in The Netherlands is presented in
Fig. 1. Since June 2002, a conjugated vaccine against
serogroup C has been included in the national immunization
program. In 2009, 84% of isolates belonged to serogroup B,
7% to serogroup C, and the remaining to other serogroups,
such as X, Y , and W135 [5]. Thus, the advised vaccination
only offers limited protection. The peak incidence of
serogroup B meningococcal disease is in children younger
than 5 years and between the age of 15 to 19 years. Based on
the risk of meningococcal infection in children treated with
eculizumab and the high prevalence of serogroup B disease
that cannot yet be prevented by vaccination, penicillin
prophylaxis should not only be considered [6] but strongly
advised to patients. Beside this, vaccination with a conjugated
vaccine might give better protection than the unconjugated
polysaccharide vaccine [7]. Serogroup B prevalence is highest
not only in The Netherlands but in the rest of Europe and
other parts of the world [8]. The best strategy depends on the
distribution of meningococcal serogroups and the availability
of vaccines in different countries [9].
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Fig. 1 Distribution of meningo-
coccal serogroups 1959–2009
(adapted from Netherlands
Reference Laboratory for
Bacterial Meningitis, used with
permission)
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